SMASAC, la manufacturera peruana: una experiencia del inicio de la gestión cultural 2021-2022

Laboratorio SMASAC es una organización manufacturera que durante sus 38 años de existencia ha tenido como prioridad principal su actividad primaria: la producción de productos para sus clientes. Sin embargo, en la búsqueda de la mejora en la competitividad y productividad dentro del mercado manufacturero, vio la necesidad de adaptarse a las nuevas exigencias de los clientes para quienes actualmente es importante ser una marca con propósito. Esto significa no solo trabajar por motivos económicos, sino tener una razón de existir y de hacer lo que hace, materializando su propósito en los productos o servicios que ofrece y en las acciones que realiza, conectando mejor con sus clientes y colaboradores. Es por eso que, una de las principales acciones internas a realizar es mejorar su clima laboral de la mano de una cultura organizacional sólida, que motive a sus colaboradores y que estos no solo estén informados de qué los define, sino también que se comporten y relacionen considerando lo que define a la organización, para lo que se debe implementar un fuerte sistema de creencias que aporte a su ventaja diferencial en su rubro de mercado; es decir, el conjunto de los principales elementos identitarios de su cultura organizacional. Pero esto implica principalmente un cambio en la gerencia conservadora que tiene la empresa. Respondiendo a esta necesidad, desde el año 2021 se fue gestando un cambio paulatino de la gestión organizacional. Como primera acción, se incorporó en el organigrama institucional el área de Transformación Organizacional, que tiene como finalidad gestar cambios en la organización desde las áreas de comunicación interna, capacitación y desarrollo con acciones que fortalezcan e involucren a los colaboradores con la cultura organizacional y mejoren el clima laboral. Es esta área la que expone en el siguiente trabajo los retos que tiene para poder gestar el camino hacia un cambio en la visión de la gerencia general y, la principal acción que surge con motivo de este cambio: el desarrollo de una guía de cultura. Esta herramienta marca un antes y un después dentro de la organización ya que su existencia ratifica la preocupación y compromiso de la gerencia general por la gestión del bienestar de sus colaboradores a través de la formalización de su gestión cultural, donde se refleje un buen clima laboral con colaboradores más productivos, motivados y satisfechos.SMASAC Laboratory is a manufacturing organization that, over its 38 years of existence, has placed its primary focus on its core activity: the production of products for its clients. However, in the pursuit of enhancing competitiveness and productivity within the manufacturing market, it recognized the imperative to adapt to the evolving demands of its customers, for whom being a purpose-driven brand is now of utmost importance. This signifies not only working for economic motives but having a reason for existence and for undertaking its actions, embodying its purpose in the products or services it provides, and in the actions it takes, fostering stronger connections with its customers and collaborators. That's why one of the key internal actions to be undertaken is enhancing its work environment alongside a robust organizational culture, one that inspires its collaborators. Not only should they be well-informed about what defines them, but they should also conduct themselves and relate to others in alignment with the organization's defining aspects. To achieve this, a strong belief system must be implemented that contributes to their competitive edge in the market sector. This implies incorporating the core identifying elements of their organizational culture. However, this primarily involves a shift in the conservative management that the company currently possesses. In response to this necessity, a gradual shift in organizational management has been taking shape since 2021. As a first step, the institutional hierarchy welcomed the establishment of the Organizational Transformation department. This department is tasked with instigating changes within the organization through initiatives within internal communication, training, and development. These efforts are designed to strengthen and engage employees with the organizational culture, leading to an enhanced work environment. It's this area that presents in the following work the challenges it faces in order to pave the way for a change in the general management's perspective, and the main action that arises as a result of this change: the development of a culture guide. This tool marks a turning point within the organization, as its existence reaffirms the concern and commitment of the general management towards the well-being of its collaborators through the formalization of its cultural management. This is meant to reflect a positive work environment with more productive, motivated, and satisfied employees

Prevalencia del biotipo facial según el análisis cefalométrico de Ricketts en radiografías obtenidas en un centro radiológico Arequipa 2020

La investigación tuvo como objetivo determinar el biotipo facial según el análisis cefalométrico de ricketts en radiografías obtenidas en un centro radiológico en Arequipa, durante el año 2020. Fue un estudio de diseño no experimental, transversal, descriptivo y retrospectivo. La muestra estuvo conformada por 600 radiografías cefalométricas del centro radiológico con un rango de edad de 9 a 57 años. Las radiografías cefalométricas fueron obtenidas mediante el equipo radiológico RAYSCAN, el análisis mediante el software RADIOCEF Studio 2; para la recolección de los datos se utilizó índice de VERT. Los resultados mostraron que el biotipo facial encontrado fue en un 36,5% Mesofacial, 18,7% Braqui severo, 15,5% Braquifacial, 13,3% Dolico suave, 12,3% Dolicofacial y 3,7% Dolico severo. Se reportó también que, según el sexo, en la población masculina el más predominante es el mesofacial con el 37 %; de igual modo sucede en la población femenina, en cuyo caso representa al 36,1%. Por último, según el grupo etario, el 46,8 % de los niños posee un biotipo facial Mesofacial, siendo este el más predominante que en los adolescentes representado en el 31,3%, en jóvenes el 34,6% y en adultos el 39,6%. Se concluye que el biotipo facial prevalente, es el Mesofacial

Actividad antibacterial de nanopartículas de óxido de zinc sobre Listeria monocytogenes ATCC 7644

background: Zinc oxide nanoparticles (Np-ZnO) have different behaviors which allows its application in various areas. Objectives: To determine the minimum inhibitory concentration (MIC) of Zinc oxide nanoparticles for Listeria monocytogenes ATCC 7644. The study: Zinc oxide nanoparticles with an average size of 90nm and different concentrations of 4; 2; 1; 0,5; 0,25; 0,12; 0,06; 0,03; 0,01; 0,007 mg/mL prepared in aqueous solution were used. It was incubated at a time corresponding to generation time of the bacteria, evaluating the growth with the presence of turbidity. Findings: The MIC for Listeria monocytogenes ATCC 7644 was 0,06 mg/mL. Conclusion: The minimum inhibitory concentration (MIC) of Zinc oxide nanoparticles (Np-ZnO) with an average size of 90nm for Listeria monocytogenes ATCC 7644 was 0,06 mg/mL, enough value to significantly control the growth of for Listeria monocytogenes ATCC 7644.Introducción: Las nanopartículas de óxido de zinc (Np-ZnO) presentan diferentes comportamientos; permitiendo su aplicación en diversas áreas. Objetivos: Determinar cuál es la concentración mínima inhibitoria de nanopartículas de óxido de zinc sobre el crecimiento de Listeria monocytogenes ATCC 7644. El estudio: Se utilizaron nanopartículas de ZnO con un tamaño promedio de 90 nm, a diferentes concentraciones de 4; 2; 1; 0,5; 0,25; 0,12; 0,06; 0,03; 0,01; 0,007 mg/mL de Np-ZnO, preparadas en solución acuosa. Se incubó en un tiempo correspondiente al de generación de la bacteria, evaluando el crecimiento con la aparición de turbidez. Hallazgos: Listeria monocytogenes ATCC 7644 presentó una CMI de 0,06 mg/mL. Conclusión: La concentración mínima inhibitoria (CMI) resultante para las nanopartículas de óxido de zinc (Np-ZnO) de 90 nm de tamaño promedio fue de 0,06 mg/mL, suficiente para controlar significativamente el crecimiento contra Listeria monocytogenes ATCC 7644

Saturación sensorial y lactancia materna como métodos analgésicos no farmacológicos: estudio randomizado controlado.

OBJETIVOVerificar el efecto analgésico de la saturación sensorial (Sat) y compararlo con la lactancia materna (LM) y un grupo control.MATERIAL Y MÉTODOSEnsayo clínico, randomizado con 167 recién nacidos a término sanos, en quiénes se cuantificó la intensidad de dolor agudo al recibir una vacuna (hepatitis  B) a las 48 horas de vida. Se formaron tres grupos de manera aleatoria: grupo 1 (control, sin método analgésico), grupo 2 (analgesia con LM) y grupo 3 (analgesia con Sat); los estímulos sensoriales fueron: táctil (caricias de la madre sobre el rostro y espalda), olfatorio (colonia sin alcohol), auditivo (voz de la madre), gustativo (lactancia materna), visual (rostro de la madre frente a su bebé). Se utilizó la Escala para Dolor Agudo Neonatal (DAN: Douleur Aiguë du Nouveau-né), con un score de dolor del 1 al 10 y 7 categorías de dolor.RESULTADOSEl grupo con saturación sensorial tuvo menos dolor (3.02 en la escala de DAN); el grupo dos (lactancia materna): 4.15, y control: 9.02.   Hubo diferencia significativa entre grupos. Dolor extremo, se presentó en 60% del grupo control, 3,8% en el grupo lactancia materna y 0% en el grupo con saturación sensorial. La categoría NO DOLOR fue más frecuente en el grupo tres (Sat): 33,3% versus 16,9% del grupo con LM y 0% grupo control, p<0.0001.CONCLUSIONESLa saturación sensorial tuvo mayor efecto analgésico que la lactancia materna. Ambas demostraron buen efecto analgésico, comparadas con el grupo control. (Rev Horiz Med 2011;11(2):80

Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents

This is the peer reviewed version of the following article: Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. Journal of Gastroenterology and Hepatology (2020): 29 April, which has been published in final form at https://doi.org/10.1111/jgh.15084. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived VersionsBiological therapies may be changing the natural history of inflammatory bowel diseases, reducing the need for surgical intervention. We aimed to assess whether the availability of anti‐TNF agents impacts the need for early surgery in Crohn's disease (CD) and ulcerative colitis (UC). Methods Retrospective, cohort study of patients diagnosed within a 6‐year period before and after the licensing of anti‐TNFs (1990‐1995 and 2007‐2012 for CD; 1995‐2000 and 2007‐2012 for UC) were identified in the ENEIDA Registry. Surgery‐free survival curves were compared between cohorts. Results A total of 7,370 CD patients (2,022 in Cohort 1 and 5,348 in Cohort 2) and 8,069 UC patients (2,938 in Cohort 1 and 5,131 in Cohort 2) were included. Immunosuppressants were used significantly earlier and more frequently in both CD and UC post‐biological cohorts. The cumulative probability of surgery was lower in CD following anti‐TNF approval (16% and 11%, 22% and 16%, and 29% and 19%, at 1, 3 and 5 years, respectively p<0.0001), though not in UC (3% and 2%, 4% and 4%, and 6% and 5% at 1, 3 and 5 years, respectively; p=0.2). Ileal involvement, older age at diagnosis and active smoking in CD, and extensive disease in UC, were independent risk factors for surgery, whereas high‐volume IBD centres (in both CD and UC) and immunosuppressant use (in CD) were protective factors. Conclusions Anti‐TNF availability was associated with a reduction in early surgery for CD (driven mainly by earlier and more widespread immunosuppressant use) but not in U

Transforming observational data and theoretical isochrones into the ACS/WFC Vega-mag system

We propose a zero-point photometric calibration of the data from the ACS/WFC on board the Hubble Space Telescope, based on a spectrum of Vega and the most up to date in-flight transmission curves of the camera. This calibration is accurate at the level of a few hundredths of a magnitude. The main purpose of this effort is to transform the entire set of evolutionary models by Pietrinferni et al. (2004) into a simple observational photometric system for ACS/WFC data, and make them available to the astronomical community. We provide the zero points for the most used ACS/WFC bands, and give basic recipes for calibrating both the observed data and the models. We also present the Colour Magnitude Diagram (CMD) from ACS data of 5 Galactic globular clusters, spanning the metallicity range -2.2<[Fe/H]<-0.04, and provide fiducial points representing their sequences from several magnitudes below the turnoff to the red giant branch tip. The observed sequences are compared with the models in the newly defined photometric system.Comment: 10 pages, 3 figures, 7 Tables. Accepted (2004 Dec 14) on M.N.R.A.

Antitumor Necrosis Factor Agents to Treat EndoscopicPostoperative Recurrence of Crohn’s Disease: A Nationwide Study With Propensity-Matched Score Analysis

INTRODUCTION:Patients with Crohn's disease experiencing endoscopic postoperative recurrence (POR) may benefit from antitumor necrosis factor (TNF) agents but scarce data on this are available. Our aim was to assess the efficacy of anti-TNF in improving mucosal lesions in patients with endoscopic POR.METHODS:Multicenter, retrospective, study of patients with Crohn's disease who underwent therapy with anti-TNF agents for endoscopic POR (Rutgeerts score > i1). Treatment outcomes were assessed by the findings in the last ileocolonoscopy performed after anti-TNF therapy was initiated. Endoscopic improvement and remission were defined as any reduction in the baseline Rutgeerts score and by a Rutgeerts score < i2, respectively.RESULTS:A total of 179 patients were included, 83 were treated with infliximab and 96 with adalimumab. Median time on anti-TNF therapy at the last endoscopic assessment was 31 months (interquartile range, 13-54). Endoscopic improvement was observed in 61%, including 42% who achieved endoscopic remission. Concomitant use of thiopurines and treatment with infliximab were associated with endoscopic improvement (odds ratio [OR] 2.15, 95% confidence interval [CI] 1.04-4.46; P = 0.03, and OR 2.34, 95% CI 1.18-4.62; P < 0.01, respectively) and endoscopic remission (OR 3.16, 95% CI 1.65-6.05; P < 0.01, and OR 2.01, 95% CI 1.05-3.88; P = 0.04, respectively) in the multivariable logistic regression analysis. These results were confirmed in a propensity-matched score analysis.DISCUSSION:In patients with endoscopic POR, anti-TNF agents improve mucosal lesions in almost two-thirds of the patients. In this setting, concomitant use of thiopurines and use of infliximab seem to be more effective in improving mucosal lesions.Fiorella Canete received a research grant from the Societat Catalana de Digestologia

Role of immunotherapy in Ewing sarcoma

Ewing sarcoma (ES) is thought to arise from mesenchymal stem cells and is the second most common bone sarcoma in pediatric patients and young adults. Given the dismal overall outcomes and very intensive therapies used, there is an urgent need to explore and develop alternative treatment modalities including immunotherapies. In this article, we provide an overview of ES biology, features of ES tumor microenvironment (TME) and review various tumor-associated antigens that can be targeted with immune-based approaches including cancer vaccines, monoclonal antibodies, T cell receptor-transduced T cells, and chimeric antigen receptor T cells. We highlight key reasons for the limited efficacy of various immunotherapeutic approaches for the treatment of ES to date. These factors include absence of human leukocyte antigen class I molecules from the tumor tissue, lack of an ideal surface antigen, and immunosuppressive TME due to the presence of myeloid-derived suppressor cells, F2 fibrocytes, and M2-like macrophages. Lastly, we offer insights into strategies for novel therapeutics development in ES. These strategies include the development of gene-modified T cell receptor T cells against cancer–testis antigen such as XAGE-1, surface target discovery through detailed profiling of ES surface proteome, and combinatorial approaches. In summary, we provide state-of-the-art science in ES tumor immunology and immunotherapy, with rationale and recommendations for future therapeutics development

Phase I Trial of Oral Yeast-Derived &beta;-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma

Beta glucans, complex polysaccharides, prime leukocyte dectin-1 and CR3-receptors and enhance anti-tumor cytotoxicity of complement-activating monoclonal antibodies. We conducted a phase I study (clinicaltrials.gov NCT00492167) to determine the safety of the combination of yeast-derived beta glucan (BG) and anti-GD2 murine monoclonal antibody 3F8 in patients with relapsed or refractory high-risk neuroblastoma. Patients received intravenous 3F8 (fixed dose of 10 mg/m2/day &times; 10 days) and oral BG (dose-escalated from 10&ndash;200 mg/kg/day &times; 17 days in cohorts of 3&ndash;6 patients each). Forty-four patients completed 141 cycles. One patient developed DLT: transient self-limiting hepatic transaminase elevation 5 days after starting BG (120 mg/kg/day). Overall, 1, 3, 12 and 24 evaluable patients had complete response, partial response, stable and progressive disease, respectively, at the end of treatment. Positive human anti-mouse antibody response and dectin-1 rs3901533 polymorphism were associated with better overall survival. BG dose level and serum BG levels did not correlate with response. Progression-free and overall survival at 2 years were 28% and 61%, respectively. BG lacked major toxicity. Treatment with 3F8 plus BG was associated with anti-neuroblastoma responses in patients with resistant disease. Although the maximal tolerated dose for yeast BG was not reached, considering the large volume of oral BG, we recommended 40 mg/kg/day as the phase II dose

II Congreso latinoamericano de investigación en Hoteleria y Restauración Dia 2 Sala B

"La Facultad de Administración en Hotelería y Turismo de la Universidad Peruana de Ciencias Aplicadas, el CETT Barcelona School of Tourism, Hospitality and Gastronomy (Universitat de Barcelona) y la Facultad de Administración de Empresas Turísticas y Hoteleras de la Universidad Externado de Colombia organizan la segunda edición del Congreso Latinoamericano de Investigación en Hotelería y Restauración. En esta ocasión, la UPC será el centro anfitrión del evento. El sector del alojamiento turístico ha cobrado relevancia a nivel mundial en los últimos años; por ello, este evento invita a reflexionar a investigadores, profesionales, académicos y estudiantes de la industria de la hospitalidad sobre los retos y oportunidades del sector en el escenario actual y futuro, en la búsqueda de una industria cada vez más competitiva y sostenible. En este sentido, los ejes temáticos a tratar en el Congreso son: • Nuevas Tecnologías • Satisfacción del Cliente • Comportamiento del Consumidor • Revenue Management • Marketing digital • Sostenibilidad • Gestión de Crisis • Gestión de Personas En la segunda edición del Congreso Latinoamericano de Investigación en Hotelería y Restauración, se contará con espacios dedicados a la divulgación de resultados de investigaciones realizados principalmente en Latinoamérica. Del mismo modo, ponencias y mesas de discusión con destacados participantes del ámbito empresarial, gubernamental y académico.